DiaMedica Inc. (DiaMedica) is a development-stage biopharmaceutical company. The Company is focused on unmet diseases, including acute vascular disease of the brain, kidney and heart. The Company's focus is on acute ischemic stroke (AIS) and acute kidney injury indications. Its lead product, DM199, is a recombinant human tissue kallikrein-1 protein (rhKLK1), a therapy engineered to improve endothelial function by vasodilation and by inducing new blood vessel growth (angiogenesis). The Company is pursuing the development of DM199 in acute vascular disease of the brain, kidney and heart with AIS as the lead initiative. It has completed a Phase I b of DM199 in T2D patients. DiaMedica's recombinant form of tissue kallikrein-1 treats a spectrum of clinical scenarios where re-establishing blood flow and reducing inflammation in patients is vital to preserving organ function, such as brain, kidney and heart. The Company has not commercialized its products and has not generated any revenues.